Evidence map›Paper›PMID 29587668›Full record

ArticleBMC cancer2018

Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo-γ-linolenic acid peroxidation dependent mechanism.

Yi Xu, Xiaoyu Yang, Tao Wang, Liu Yang, Yu-Ying He, Keith Miskimins, Steven Y Qian

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. 2D Nanomaterial, TiBiosensors · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Yi XuDepartment of Pharmaceutical Sciences, North Dakota State University, Fargo, ND, 58108, USA.
Xiaoyu YangDepartment of Pharmaceutical Sciences, North Dakota State University, Fargo, ND, 58108, USA.
Tao WangDepartment of Pharmaceutical Sciences, North Dakota State University, Fargo, ND, 58108, USA.
Liu YangDepartment of Transplantation, Mayo Clinic Florida, Jacksonville, FL, 32224, USA.
Yu-Ying HeDepartment of Medicine, Section of Dermatology, University of Chicago, Chicago, USA.
Keith MiskiminsCancer Biology Research Center, Sanford Research, Sioux Falls, SD, 57104, USA.
Steven Y QianDepartment of Pharmaceutical Sciences, North Dakota State University, Fargo, ND, 58108, USA. steven.qian@ndsu.edu.ORCID 0000-0001-9236-6189
North Dakota State University · USMayo Clinic in Florida · USSanford Research · USUniversity of Chicago · US

Funding

Targeting CLEC-2/podoplanin as a therapeutic strategy for pancreatic cancerP20GM109024 · NIGMS · NORTH DAKOTA STATE UNIVERSITY · PI Sanku Mallik · 2016 to 2026
$20.5M
New Paradigm of Targeting COX-Catalyzed Free Radical Peroxidation in Colon CancerR15CA195499 · NCI · NORTH DAKOTA STATE UNIVERSITY · PI GUO, ANG · 2016 to 2016
$435k
National Institute of General Medical Sciences (US) P20GM109024NCI NIH HHS R15 CA195499NCI NIH HHS R15CA195499NIGMS NIH HHS P20 GM109024Sanford Health-NDSU Seed Grant FAR0026507
6 · The paper itself

Abstract

backgroundCyclooxygenase-2 (COX-2), the inducible COX form, is a bi-functional membrane-bound enzyme that typically metabolizes arachidonic acid (downstream ω-6 fatty acid) to form 2-series of prostaglandins known to be involved in cancer development. Overexpression of COX-2 has been found in a majority of breast carcinomas, and has also been associated with increased severity and the development of the metastasis. Our lab recently demonstrated that COX-2 can also metabolize dihomo-γ-linolenic acid (DGLA, a precursor of ω-6 arachidonic acid) to produce an anti-cancer byproduct, 8-hydroxyoctanoic acid (8-HOA) that can inhibit growth and migration of colon and pancreatic cancer cells. We thus tested whether our strategy of knocking down delta-5-desaturase (D5D, the key enzyme that converts DGLA to arachidonic acid) in breast cancer cells overexpressing COX-2 can also be used to promote 8-HOA formation, thereby suppressing cancer growth, migration, and invasion.

methodsSiRNA and shRNA transfection were used to knock down D5D expression in MDA-MB 231 and 4 T1 cells (human and mouse breast cancer cell lines expressing high COX-2, respectively). Colony formation assay, FITC Annexin V/PI double staining, wound healing and transwell assay were used to assess the effect of our strategy on inhibition of cancer growth, migration, and invasion. GC/MS was used to measure endogenous 8-HOA, and western blotting was performed to evaluate the altered key protein expressions upon the treatments.

resultsWe demonstrated that D5D knockdown licenses DGLA to inhibit growth of breast cancer cells via promoting formation of 8-HOA that can inhibit histone deacetylase and activate cell apoptotic proteins, such as procaspase 9 and PARP. Our strategy can also significantly inhibit cancer migration and invasion, associated with altered expression of MMP-2/- 9, E-cadherin, vimentin and snail. In addition, D5D knockdown and DGLA supplementation greatly enhanced the efficacy of 5-fluorouracil on breast cancer growth and migration.

conclusionsConsistent to our previous studies on colon and pancreatic cancer, here we demonstrate again that the high level of COX-2 in breast cancer cells can be capitalized on inhibiting cancer growth and migration. The outcome of this translational research could guide us to develop new anti-cancer strategy and/or to improve current chemotherapy for breast cancer treatment.

Indexed as

Gene ExpressionLipid Peroxidation8,11,14-Eicosatrienoic AcidApoptosisBreast NeoplasmsCaprylatesCell Line, TumorCell MovementCell ProliferationCyclooxygenase 2Delta-5 Fatty Acid DesaturaseFatty Acid DesaturasesFemaleFluorouracilGene Knockdown TechniquesHumans8,11,14-Eicosatrienoic Acid8-hydroxyoctanoic acidCaprylatesCyclooxygenase 2Delta-5 Fatty Acid DesaturaseFatty Acid DesaturasesFluorouracilbreast cancer growth, migration and invasionCOX-catalyzed DGLA peroxidationD5D knockdown MDA-MB 231 and 4 T1 cellsdelta-5-desaturase

Identifiers

PMID29587668
PMCPMC5870477
OpenAlexW2802628431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.